Sotera Health Co

Sotera Health Co(SHC)股票分析

$17.890

-0.179 (-1.00%)收盤時

Loading chart…
最高
18.520
開盤
18.130
成交量加權均價
18.07
成交量
1.86M
市值
3.37B
最低
17.790
成交金額
33.53M
企業價值/稅息折舊攤銷前利潤(TTM)
11.28

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

AI 分析 of Sotera Health Co (SHC)

買進

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

估值指標

Sotera Health Co(SHC)目前預期本益比為 17.76,5 年平均預期本益比為 18.02。

預期本益比

合理
5 年均值 P/E
18.02
目前P/E
17.76
高估
21.72
低估
14.31

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
11.45
目前EV/EBITDA
11.28
高估
13.65
低估
9.26

預期股價營收比

合理
5 年均值 P/S
3.96
目前P/S
3.91
高估
5.09
低估
2.83

Alphio AI 對 SHC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SHC

$12.30

情境價格

基

基準

基準 · 50%SHC

$11.71

情境價格

悲

悲觀

悲觀 · 25%SHC

$10.60

情境價格

持有 SHC 的大戶

L

Lakewood Capital Management, LP

+ 持有SHC

+6.37%

3個月報酬率

S

Sculptor Capital Management, Inc.

+ 持有SHC

-4.60%

3個月報酬率

V

Voss Capital, LP

+ 持有SHC

-5.54%

3個月報酬率

A

Ancora Advisors LLC

+ 持有SHC

-6.03%

3個月報酬率

G

Greenlight Capital, Inc.

+ 持有SHC

-6.98%

3個月報酬率

T

Two Seas Capital LP

+ 持有SHC

-10.94%

3個月報酬率

事件時間軸

2026-08-06 (ET)

07:30:00

Sotera Health Q2 Revenue Reaches $321.38M, Exceeds Expectations

07:30:00

Consensus Raises FY26 Revenue Outlook to $1.24B

2026-05-12 (ET)

09:30:00

Goldman Sachs Sole Bookrunner, Deal Range $15.27-$15.43

2026-05-11 (ET)

17:30:00

Goldman Sachs Acts as Sole Book Running Manager for Offering

16:40:00

Sotera Health Company Launches Secondary Offering of 31.84M Shares

資訊

SHC 常見問題 —— 由 Alphio AI 解答

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易